CYTK
Cytokinetics Inc

4,562
Mkt Cap
$7.44B
Volume
2.56M
52W High
$70.98
52W Low
$29.31
PE Ratio
-9.25
CYTK Fundamentals
Price
$62.42
Prev Close
$60.41
Open
$60.35
50D MA
$63.91
Beta
0.93
Avg. Volume
1.86M
EPS (Annual)
-$6.54
P/B
-11.26
Rev/Employee
$130,815.75
$8,030.25
Loading...
Loading...
News
all
press releases
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
Key Points15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026...
Nasdaq News: Markets·13h ago
News Placeholder
More News
News Placeholder
GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK
GW&K Investment Management LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the...
MarketBeat·3d ago
News Placeholder
GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK
GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the third quarter, according to its most recent disclosure...
MarketBeat·3d ago
News Placeholder
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 26,000 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $61.87...
MarketBeat·4d ago
News Placeholder
Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK
Segall Bryant & Hamill LLC lifted its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 116.1% during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·5d ago
News Placeholder
Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK
Royce & Associates LP bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·5d ago
News Placeholder
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK
Legato Capital Management LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·6d ago
News Placeholder
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK
Rafferty Asset Management LLC trimmed its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 39.3% in the 3rd quarter, according to the company in its most recent Form 13F filing...
MarketBeat·7d ago
News Placeholder
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-one analysts that are currently covering the company, Marketbeat...
MarketBeat·7d ago
News Placeholder
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB
Handelsbanken Fonder AB boosted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 626.0% during the 3rd quarter, according to the company in its most recent filing...
MarketBeat·8d ago
<
1
2
...
>

Latest CYTK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.